Genome editing for inborn errors of metabolism: advancing towards the clinic

作者：Jessica L. Schneller, Ciaran M. Lee, Gang Bao, Charles P. Venditti · 发表于：BMC Medicine · 年份：2017 · DOI：10.1186/s12916-017-0798-4 · 被引用次数：55 · 研究领域：CRISPR and Genetic Engineering、Biochemical and Molecular Research、Virus-based gene therapy research

Inborn errors of metabolism (IEM) include many disorders for which current treatments aim to ameliorate disease manifestations, but are not curative. Advances in the field of genome editing have recently resulted in the in vivo correction of murine models of IEM. Site-specific endonucleases, such as zinc-finger nucleases and the CRISPR/Cas9 system, in combination with delivery vectors engineered to target disease tissue, have enabled correction of mutations in disease models of hemophilia B, hereditary tyrosinemia type I, ornithine transcarbamylase deficiency, and lysosomal storage disorders. These in vivo gene correction studies, as well as an overview of genome editing and future directions for the field, are reviewed and discussed herein.